Health Care • Biotechnology: Pharmaceutical Preparations
$50.81 ▼ -1.37
(-2.63%)
MKT CAP: $1.49B • VOL: 557.2K
52W L $14 52W H $66
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$43
MEDIAN
$57
MEAN
$58
HIGH
$69
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ETON TAPE
ETON // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $61.48 | $58.43 | 2025-02-14 | $46.24 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $64.02 | $59.96 | 2025-02-06 | $47.76 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $57.92 | $55.89 | 2025-01-29 | $48.78 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $51.83 | — | 2025-01-17 | $49.79 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $44.71 | $48.27 | 2025-01-09 | $45.22 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $60.46 | $52.84 | 2024-12-18 | $44.20 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $49.29 | $51.32 | 2024-12-04 | $47.25 | -4.3% | 48% | C |